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CTX-M-55-Type Extended-Spectrum β-lactamase-
Producing Shigella sonnei Isolated from a Korean 
Patient Who Had Travelled to China
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We report a case of CTX-M-55-type extended-spectrum β-lactamase (ESBL)-producing 
Shigella sonnei infection in a 27-year-old Korean woman who had traveled to China. The 
patient was admitted to the hospital due to abdominal pain, watery diarrhea, and fever 
(39.3˚C). S. sonnei was isolated from her stool specimens, and the pathogen was found to 
be resistant to cefotaxime due to CTX-M-55-type ESBL. Insertion sequence (IS)Ecp1 was 
found upstream of the blaCTX-M-55 gene. The blaCTX-M-55 gene was transferred from the S. 
sonnei isolate to an Escherichia coli J53 recipient by conjugation. Pulsed-field gel electro-
phoresis and Southern blotting revealed that the blaCTX-M-55 gene was located on a plasmid 
of approximately 130 kb. 
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INTRODUCTION
Shigellosis is very rare in Korea, but people who travel to certain 
countries may acquire the infection. The bacteria are excreted 
through feces and are transmitted by ingestion of contaminated 
food and water [1]. To reduce the severity of the clinical course 
of illness and the duration of fecal excretion of bacteria, the 
WHO recommends ciprofloxacin as the first-line treatment for 
shigellosis [2, 3]. Ampicillin and trimethoprim-sulfamethoxazole 
are no longer sufficiently effective due to increases in the bacte-
rial resistance to these drugs [4]. Because of concerns regard-
ing the adverse effects of ciprofloxacin in children and an in-
crease in the resistance to ciprofloxacin, third generation cepha-
losporins are frequently used as alternative treatments [2, 4]. 
However, Shigella species producing CTX-M-type β-lactamase 
are frequently being reported in some parts of the world [1, 5-7]. 
CTX-M-type β-lactamase is one of the most common extended-
spectrum β-lactamases (ESBL), and it confers resistance to all 
β-lactams except cephamycins and carbapenems [8]. The 
spread of CTX-M type ESBL-producing Shigella species has be-
come of concern worldwide because the increasing circulation 
of this resistant strain further narrows the choice of effective an-
tibiotics. In Korea, only CTX-M-14-producing Shigella sonnei 
have been reported [9-11]. 
 We report the isolation of CTX-M-55-producing S. sonnei from 
a Korean woman who was admitted to the hospital due to ab-
dominal pain, watery diarrhea, and fever (39.3˚C) immediately 
after having traveled to China. 
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A 27-yr-old woman was admitted to the hospital with watery di-
arrhea, abdominal pain, and fever (39.3˚C) on the day of her re-
turn from a 4-day trip to China. Laboratory investigation showed 
a peripheral blood leukocyte count of 8.2×109/L with 80% poly-
morphonuclear cells and a C-reactive protein level of 107 mg/L. 
Stool samples were inoculated on MacConkey and SS agar (BD 
Diagnostics Systems, Sparks, MD, USA) and incubated at 37˚C 
for 20 hr, and colorless medium-sized colonies developed. The 
bacterium was identified as S. sonnei using the Vitek2 GN ID 
card (bioMérieux, Marcy l’Etoile, France); a positive slide agglu-
tination test with a Shigella serogroup D antiserum (Joong 
Kyeom Co., Anshan, Korea) confirmed the identification. 
 The pathogen’s antimicrobial susceptibility was initially deter-
mined by the VITEK 2 AST N131 card (bioMérieux, Marcy l’Etoile, 
France). ESBL production was confirmed by the double disk 
synergy test using cefotaxime (30 μg), ceftazidime (30 μg) and 
amoxicillin-clavulanic acid (20/10 μg) disks (BD Diagnostics 
Systems) [12]. Minimum inhibitory concentrations (MICs) were 
determined by the CLSI agar dilution method or by the Etest (AB 
bioMérieux, Solna, Sweden) (Table 1). The isolate was resistant 
to cephalothin, aztreonam, and cefotaxime, but susceptible to 
cefoxitin and intermediate to ceftazidime. The patient was treated 
with oral ciprofloxacin, after which her symptoms began to im-
prove. She was discharged 4 days after admission.  
 To determine the genetic characteristics of the ESBL, PCR and 
sequencing were carried out as described previously [13]. These 
investigations identified the ESBL as being encoded by blaCTX-M-55, 
which is identical to blaCTX-M-57 [14]. The blaCTX-M-55 gene and sur-
rounding regions were investigated by PCR and sequencing [12], 
and insertion sequence (IS)Ecp1 was found to be upstream of 
blaCTX-M-55. The blaCTX-M-55 gene was successfully transferred from 
the S. sonnei isolate to an Eecherichia coli J53 (azideR) recipient 
by plate mating. MacConkey agar containing cefotaxime (2 μg/
mL) and sodium azide (100 μg/mL) was used as the selective 
media. The β-lactam resistance patterns of the S. sonnei isolate 
and the transconjugant were similar, but the MICs of ceftazidime 
and aztreonam for the transconjugant were increased 2-fold, 
from 8 μg/mL and 24 μg/mL to 16 μg/mL and 48 μg/mL, respec-
tively (Table 1). To estimate the size of the plasmid harboring 
blaCTX-M-55, genomic DNA from S. sonnei isolate and its transcon-
jugant were digested with S1 nuclease and separated by pulsed-
field gel electrophoresis [15]. Southern blotting was performed on 
the agarose gels by in-gel hybridization with a blaCTX-M-55 probe la-
beled with digoxigenin (Roche Diagnostics, Indianapolis, IN, 
USA) [15]. This experiment showed that blaCTX-M-55 was located on 
a plasmid of approximately 130 kb in each of the strains (Fig. 1). 
Replicon typing of the plasmid by PCR was unsuccessful [16]. 
Table 1. Antimicrobial susceptibility of the clinical isolate, transcon-
jugant, and Escherichia coli J53 recipient determined by the Etest 
or the agar dilution method
Antibiotics
MIC (µg/mL)
Shigella sonnei Transconjugant Escherichia coli J53
Ampicillin >256 >256 4
Piperacillin* >128 >128 1
A mpicillin- 
sulbactam*
16 16 8
A moxicillin- 
clavulanic acid
6 6 6
Cephalothin >256 >256 4
Cefoxitin* 4 8 2
Cefotaxime 128 128 0.064
Ceftazidime 8 16 0.125
Cefepime 8 12 0.064
Aztreonam 24 48 0.125
Ciprofloxacin* 0.12 0.03 0.032
T rimethoprim- 
sulfamethoxazole
>32 0.032 0.032
Imipenem 0.25 0.25 0.25
Meropenem* 0.03 0.03 0.064
Colistin* 0.5 0.5 0.25
*MIC was determined by the agar dilution method.
Abbreviation: MIC, minimum inhibitory concentration.
Fig. 1. Pulsed-field gel electrophoresis of the S1 nuclease-digested 
genomic DNA (A) and Southern blot hybridization with the blaCTX-
M-55 probe (B). The arrow indicates plasmids in the Shigella sonnei 
isolate (lane 1) and the transconjugant (lane 2).
1 2 A 1 2 B
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DISCUSSION
CTX-M β-lactamases are plasmid-mediated ESBLs that are typi-
cally found to have high hydrolytic activity against cefotaxime [17]. 
During the last 2 decades, CTX-M β-lactamases have rapidly 
spread though the world and 133 different CTX-M β-lactamases 
are now recognized [14]. CTX-M-55 was first reported in ESBL-
producing E. coli and Klebsiella pneumoniae in Thailand during 
2004 and 2005. That study reported 7 CTX-M-55-producing iso-
lates (6 E. coli and 1 K. pneumoniae) [18]. Thereafter, CTX-M-55-
producing Enterobacteriaceae isolates have been reported in 
both humans and animals in several countries [1, 19-23]. Inter-
estingly, most of these studies have been conducted in China, 
which suggests that CTX-M-55-producing Enterobacteriaceae, in-
cluding S. sonnei, are widely disseminated throughout China [1]. 
CTX-M-55 differs from CTX-M-15 only by a single amino acid 
substitution (valine for alanine) at position 80 (Ala80Val). There-
fore, CTX-M-55 is expected to have similar hydrolytic activity as 
CTX-M-15 and to exhibit increased catalytic efficiency against 
ceftazidime as well as cefotaxime [24]. Previous studies have re-
ported that CTX-M-55-producing isolates generally show high re-
sistance to ceftazidime (MIC range from 32 to > 256 μg/mL) [13, 
18, 25, 26]. However, 2 of 3 CTX-M-55-producing S. sonnei iso-
lates from China were susceptible to ceftazidime [1]. Our isolate 
also had a relatively low MIC for ceftazidime (8 μg/mL), which 
was classified as intermediate sensitivity according to the CLSI 
breakpoints [27]. 
 The blaCTX-M genes can be transferred to other bacteria more 
readily than other plasmid-mediated bla genes because ISEcp1, 
which is frequently found upstream of the blaCTX-M genes, has an 
important role in the mobilization and expression of blaCTX-M 
genes [23, 28]. In our isolate, the blaCTX-M-55 gene was flanked by 
ISEcp1 and both were located on the plasmid. 
 Tängdén et al. [29] reported that 24 of the 100 travelers, who 
had been studied, had recently been infected with ESBL-pro-
ducing E. coli after a trip to a foreign country. Five of the 21 pa-
tients who completed a 6-month follow-up were found to be in-
fected with ESBL-producing strains. A study analyzing the dura-
tion of colonization with ESBL-producing E. coli in patients with 
travelers’ diarrhea found that 10 of the 41 patients carried 
ESBL-producing E. coli at the first follow-up (3–8 months), and 
4 patients still carried ESBL-producing E. coli after 3 yr [30]. The 
results from these studies indicate that travel to a foreign coun-
try plays an important role in the acquisition of and infection 
with ESBL-producing Enterobacteriaceae. Furthermore, these 
ESBL-producing Enterobacteriaceae can disseminate through 
the population. Specifically, the dissemination of new antimicro-
bial resistance genes may lead to major healthcare issues. In 
order to prevent the inflow of ESBL-producing Enterobacteria-
ceae, it is important to monitor suspected carriers of ESBL-pro-
ducing organisms.
 In summary, we report a case of CTX-M-55-producing S. son-
nei from a Korean patient who had just returned from China, 
suggesting that the infection was acquired during the travel. 
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